Drug resistance in Mexico: results from the National Survey on Drug-Resistant Tuberculosis

被引:21
作者
Bojorquez-Chapela, I. [1 ]
Baecker, C. E. [2 ]
Orejel, I. [3 ]
Lopez, A. [4 ]
Diaz-Quinonez, A. [2 ,5 ]
Hernandez-Serrato, M. I. [6 ]
Balandrano, S. [2 ]
Romero, M. [6 ]
Tellez-Rojo Solis, M. M. [6 ]
Castellanos, M. [3 ,6 ]
Alpuche, C. [6 ]
Hernandez-Avila, M. [6 ]
Lopez-Gatell, H. [6 ]
机构
[1] Colegio Frontera Norte, Tijuana, Baja California, Mexico
[2] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico
[3] Ctr Nacl Programas Prevent & Control Enfermedades, Mexico City, DF, Mexico
[4] Inst Nacl Estadist & Geog, Aguascalientes City, Mexico
[5] Inst Mexicano Seguro Social, Mexico City, DF, Mexico
[6] Inst Nacl Salud Publ, Cuernavaca 62100, Morelos, Mexico
关键词
pulmonary tuberculosis; multidrug-resistant tuberculosis; epidemiology; MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; PREVALENCE;
D O I
10.5588/ijtld.12.0167
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVE: To present estimations obtained from a population-level survey conducted in Mexico of prevalence rates of mono-, poly- and multidrug-resistant strains among newly diagnosed cases of pulmonary tuberculosis (TB), as well as the main factors associated with multidrug resistance (combined resistance to isoniazid and rifampicin). DESIGN: Study data came from the National Survey on TB Drug Resistance (ENTB-2008), a nationally representative survey conducted during 2008-2009 in nine states with a stratified cluster sampling design. Samples were obtained for all newly diagnosed cases of pulmonary TB in selected sites. Drug susceptibility testing (DST) was performed for anti-tuberculosis drugs. RESULTS: DST results were obtained for 75% of the cases. Of these, 82.2% (95%CI 79.5-84.7) were susceptible to all drugs. The prevalence of multidrug-resistant TB (MDR-TB) was estimated at 2.8% (95%CI 1.9-4.0). MDR-TB was associated with previous treatment (OR 3.3, 95%CI 1.1-9.4). CONCLUSIONS: The prevalence of drug resistance is relatively low in Mexico. ENTB-2008 can be used as a baseline for future follow-up of drug resistance.
引用
收藏
页码:514 / 519
页数:6
相关论文
共 18 条
[1]  
Al-Akhali A, 2007, INT J TUBERC LUNG D, V11, P1328
[2]  
[Anonymous], 2008, WHO/HTM/TB/2008.394
[3]  
[Anonymous], 2011, GLOBAL TUBERCULOSIS
[4]  
[Anonymous], 2010, WHO/HTM/TB/2010.3
[5]  
Farga V, 2011, TUBERCULOSIS
[6]   Risk factors for multidrug resistant tuberculosis in Europe: a systematic review [J].
Faustini, A ;
Hall, AJ ;
Perucci, CA .
THORAX, 2006, 61 (02) :158-163
[7]   Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997 [J].
Granich, RM ;
Balandrano, S ;
Santaella, AJ ;
Binkin, NJ ;
Castro, KG ;
Marquez-Fiol, A ;
Anzaldo, G ;
Zarate, M ;
Jaimes, ML ;
Velazquez-Monroy, O ;
Salazar, L ;
Alvarez-Lucas, C ;
Kuri, P ;
Flisser, A ;
Santos-Preciado, J ;
Ruiz-Matus, C ;
Tapia-Conyer, R ;
Tappero, JW .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :639-644
[8]   High prevalence of multidrug-resistant tuberculosis in Georgia [J].
Mdivani, Nino ;
Zangaladze, Ekaterina ;
Volkova, Natalia ;
Kourbatova, Ekaterina ;
Jibuti, Thea ;
Shubladze, Natalia ;
Kutateladze, Tamar ;
Khechinashvili, George ;
del Rio, Carlos ;
Salakaia, Archil ;
Blumberg, Henry M. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (06) :635-644
[9]  
Secretaria de Salud, 2005, NOM006SSA1993 SECR S
[10]  
SIDDIQI SH, 1989, BACTEC TB SYSTEM PRO